Search hospitals > Michigan > Ludington
Green Bay Oncology - Escanaba
Claim this profileLudington, Michigan 49431
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
245 reported clinical trials
3 medical researchers
Summary
Green Bay Oncology - Escanaba is a medical facility located in Ludington, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Green Bay Oncology - Escanaba is involved with conducting 245 clinical trials across 369 conditions. There are 3 research doctors associated with this hospital, such as Matthew L. Ryan, Brian L. Burnette, and Anthony J. Jaslowski.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Matthew L. RyanSaint Vincent Hospital Cancer Center Green Bay1 year of reported clinical research
Expert in Cancer
Studies Recurrence
45 reported clinical trials
103 drugs studied
Brian L. BurnetteSaint Vincent Hospital Cancer Center Green Bay4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
30 reported clinical trials
82 drugs studied
Anthony J. JaslowskiSaint Vincent Hospital Cancer Center Green Bay5 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
23 reported clinical trials
42 drugs studied
Clinical Trials running at Green Bay Oncology - Escanaba
Non-Small Cell Lung Cancer
Breast Cancer
Lung Cancer
Ovarian Tumors
Testicular Carcinoma
Ovarian Carcinoma
Ovarian Choriocarcinoma
Germ Cell Tumors
Testicular Choriocarcinoma
Testicular Tumor
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Green Bay Oncology - Escanaba?
Green Bay Oncology - Escanaba is a medical facility located in Ludington, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Green Bay Oncology - Escanaba is involved with conducting 245 clinical trials across 369 conditions. There are 3 research doctors associated with this hospital, such as Matthew L. Ryan, Brian L. Burnette, and Anthony J. Jaslowski.